Skip to Content

Humira Dosage

Medically reviewed by Drugs.com. Last updated on Feb 24, 2021.

Generic name: ADALIMUMAB 40mg in 0.8mL; ISOPROPYL ALCOHOL 0.70mL in 1mL
Dosage form: injection

2.1 Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

The recommended subcutaneous dosage of HUMIRA for adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) is 40 mg administered every other week. Methotrexate (MTX), other non-biologic DMARDS, glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or analgesics may be continued during treatment with HUMIRA. In the treatment of RA, some patients not taking concomitant MTX may derive additional benefit from increasing the dosage of HUMIRA to 40 mg every week or 80 mg every other week.

2.2 Juvenile Idiopathic Arthritis or Pediatric Uveitis

The recommended subcutaneous dosage of HUMIRA for patients 2 years of age and older with polyarticular juvenile idiopathic arthritis (JIA) or pediatric uveitis is based on weight as shown below. MTX, glucocorticoids, NSAIDs, and/or analgesics may be continued during treatment with HUMIRA.

Pediatric Weight
(2 Years of Age and older)
Recommended Dosage
10 kg (22 lbs) to less than 15 kg (33 lbs) 10 mg every other week
15 kg (33 lbs) to less than 30 kg (66 lbs) 20 mg every other week
30 kg (66 lbs) and greater 40 mg every other week

HUMIRA has not been studied in patients with polyarticular JIA or pediatric uveitis less than 2 years of age or in patients with a weight below 10 kg.

2.3 Crohn’s Disease

Adults

The recommended subcutaneous dosage of HUMIRA for adult patients with Crohn’s disease (CD) is 160 mg initially on Day 1 (given in one day or split over two consecutive days), followed by 80 mg two weeks later (Day 15). Two weeks later (Day 29) begin a dosage of 40 mg every other week. Aminosalicylates and/or corticosteroids may be continued during treatment with HUMIRA. Azathioprine, 6-mercaptopurine (6-MP) [see Warnings and Precautions (5.2)] or MTX may be continued during treatment with HUMIRA if necessary.

Pediatrics

The recommended subcutaneous dosage of HUMIRA for pediatric patients 6 years of age and older with Crohn’s disease (CD) is based on body weight as shown below:

Pediatric Weight
Recommended Dosage
Days 1 through 15 Starting on Day 29
17 kg (37 lbs) to
less than 40 kg (88 lbs)
Day 1: 80 mg
Day 15: 40 mg
20 mg every other week
40 kg (88 lbs) and greater Day 1: 160 mg (single dose or split over two consecutive days)
Day 15: 80 mg
40 mg every other week

2.4 Ulcerative Colitis

Adults

The recommended subcutaneous dosage of HUMIRA for adult patients with ulcerative colitis is 160 mg initially on Day 1 (given in one day or split over two consecutive days), followed by 80 mg two weeks later (Day 15). Two weeks later (Day 29) continue with a dosage of 40 mg every other week.

Discontinue HUMIRA in adult patients without evidence of clinical remission by eight weeks (Day 57) of therapy. Aminosalicylates and/or corticosteroids may be continued during treatment with HUMIRA. Azathioprine and 6-mercaptopurine (6-MP) [see Warnings and Precautions (5.2)] may be continued during treatment with HUMIRA if necessary.

Pediatrics

The recommended subcutaneous dosage of HUMIRA for pediatric patients 5 years of age and older with ulcerative colitis is based on body weight as shown below:

Pediatric Weight Recommended Dosage
Days 1 through 15 Starting on Day 29*
20 kg (44 lbs) to
less than 40 kg (88 lbs)
Day 1: 80 mg
Day 8: 40 mg
Day 15: 40 mg
40 mg every other week
or
20 mg every week
40 kg (88 lbs) and greater Day 1: 160 mg (single dose or split over two consecutive days) Day 8: 80 mg
Day 15: 80 mg
80 mg every other week
or
40 mg every week
* Continue the recommended pediatric dosage in patients who turn 18 years of age and who are well-controlled on their HUMIRA regimen.

2.5 Plaque Psoriasis or Adult Uveitis

The recommended subcutaneous dosage of HUMIRA for adult patients with plaque psoriasis (Ps) or Uveitis (UV) is an initial dose of 80 mg, followed by 40 mg given every other week starting one week after the initial dose. The use of HUMIRA in moderate to severe chronic Ps beyond one year has not been evaluated in controlled clinical studies.

2.6 Hidradenitis Suppurativa

Adults

The recommended subcutaneous dosage of HUMIRA for adult patients with hidradenitis suppurativa (HS) is an initial dose of 160 mg (given in one day or split over two consecutive days), followed by 80 mg two weeks later (Day 15). Begin 40 mg weekly or 80 mg every other week dosing two weeks later (Day 29).

Adolescents

The recommended subcutaneous dosage of HUMIRA for adolescent patients 12 years of age and older weighing at least 30 kg with hidradenitis suppurativa (HS) is based on body weight as shown below [see Use in Specific Populations (8.4) and Clinical Pharmacology (12.3)]:

Body Weight of Adolescent
Patients

(12 years of age and older)
Recommended Dosage
30 kg (66 lbs) to less than 60 kg (132 lbs)
  • Day 1: 80 mg
  • Day 8 and subsequent doses: 40 mg every other week
60 kg (132 lbs) and greater
  • Day 1: 160 mg (given in one day or split over two consecutive days);
  • Day 15: 80 mg
  • Day 29 and subsequent doses: 40 mg every week or 80 mg every other week

2.7 Monitoring to Assess Safety

Prior to initiating HUMIRA and periodically during therapy, evaluate patients for active tuberculosis and test for latent infection [see Warnings and Precautions (5.1)].

2.8 General Considerations for Administration

HUMIRA is intended for use under the guidance and supervision of a physician. A patient may self-inject HUMIRA or a caregiver may inject HUMIRA using either the HUMIRA Pen or prefilled syringe if a physician determines that it is appropriate, and with medical follow-up, as necessary, after proper training in subcutaneous injection technique.

HUMIRA can be taken out of the refrigerator for 15 to 30 minutes before injecting to allow the liquid to come to room temperature. Do not remove the cap or cover while allowing it to reach room temperature. Carefully inspect the solution in the HUMIRA Pen, prefilled syringe, or single-dose institutional use vial for particulate matter and discoloration prior to subcutaneous administration. If particulates and discolorations are noted, do not use the product. HUMIRA does not contain preservatives; therefore, discard unused portions of drug remaining from the syringe. NOTE: Instruct patients sensitive to latex not to handle the needle cover of the HUMIRA 40 mg/0.8 mL Pen and 40 mg/0.8 mL, 20 mg/0.4 mL and 10 mg/0.2 mL prefilled syringe because it may contain natural rubber latex [see How Supplied/Storage and Handling (16)].

Instruct patients using the HUMIRA Pen or prefilled syringe to inject the full amount in the syringe, according to the directions provided in the Instructions for Use [see Instructions for Use].

Injections should occur at separate sites in the thigh or abdomen. Rotate injection sites and do not give injections into areas where the skin is tender, bruised, red or hard.

If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.

The HUMIRA single-dose institutional use vial is for administration within an institutional setting only, such as a hospital, physician’s office or clinic. Withdraw the dose using a sterile needle and syringe and administer promptly by a healthcare provider within an institutional setting. Only administer one dose per vial. The vial does not contain preservatives; therefore, discard unused portions.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.